Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
Arcutis Biotherapeutics (ARQT) shares rose 10.65% to $31.89 after upgrades from Guggenheim and Cantor Fitzgerald, with price targets raised to $44 and $48 respectively. The company reported Q2 net income of $15M, up from a loss last year, driven by its eczema and psoriasis treatment Zoryve. ARQT raised its 2026 sales guidance to $525M-$540M. Institutional investors increased their holdings in Q2.
How this was made
The 30-second read
Why it matters
The dual analyst upgrades and price‑target hikes provide a clear short‑term catalyst, likely driving further buying interest.
Market read
ARQT's stock surged on fresh analyst optimism, creating a short‑term trading opportunity.
What to watch
Potential regulatory hurdles for Zoryve and competition from larger dermatology players.
Background
Arcutis Biotherapeutics is a NASDAQ‑listed biotech focused on skin‑disease treatments, with Zoryve as its lead product.
Ticker impact
Shares rose 10.65% to $31.89 after Guggenheim and Cantor upgraded the stock and raised price targets.
upward pressure as investors price in the upgraded targets
Both firms issued fresh buy/overweight calls with double‑digit target hikes, a classic catalyst for further upside.
Market effects
Positive sentiment may spill over to other biotech firms developing dermatology therapies.
Limited to US-listed biotech sector.
Minor; primarily affects ARQT and its niche market.
Counterpoint
The upgrades may be premature if Zoryve fails to meet ambitious sales forecasts.
Key entities
- AnalystGuggenheim
Upgraded ARQT to Buy with a 15.8% target increase.
- AnalystCantor Fitzgerald
Raised rating to Overweight with a higher price target.
